Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of TDV in Healthy Subjects in India
NCT06060067Phase 3Completed
- Sponsor
- Takeda
- Start
- Mar 2024
- Primary completion
- May 2025
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of live, attenuated, recombinant dengue serotypes 1, 2, 3 and 4 virus in dengue fever, sponsored by Takeda. Started Mar 2024; status: completed.
02
Drugs
live, attenuated, recombinant dengue serotypes 1, 2, 3 and 4 virus
03
Conditions
dengue fever
Beyond the preview
Go deeper on NCT06060067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06060067.